Catabasis Pharmaceuticals Inc (CATB) Receives Average Rating of “Buy” from Brokerages
Shares of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) have earned a consensus recommendation of “Buy” from the six research firms that are presently covering the company. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $5.30.
A number of research firms have issued reports on CATB. Oppenheimer Holdings Inc. set a $11.00 price target on shares of Catabasis Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, March 18th. Wedbush reissued an “ourperform” rating and set a $4.00 price target on shares of Catabasis Pharmaceuticals in a research report on Monday. Zacks Investment Research lowered shares of Catabasis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 6th. Citigroup Inc lowered shares of Catabasis Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday, February 1st. Finally, Cowen and Company lowered shares of Catabasis Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $4.00 price target for the company. in a research report on Wednesday, February 1st.
Shares of Catabasis Pharmaceuticals (NASDAQ:CATB) opened at 1.34 on Friday. Catabasis Pharmaceuticals has a 52 week low of $1.08 and a 52 week high of $7.89. The stock has a 50 day moving average of $1.43 and a 200-day moving average of $2.54. The company’s market capitalization is $25.32 million.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, March 16th. The biotechnology company reported ($0.47) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.02. On average, analysts anticipate that Catabasis Pharmaceuticals will post ($1.55) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/05/19/catabasis-pharmaceuticals-inc-catb-receives-average-rating-of-buy-from-brokerages.html.
Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new stake in Catabasis Pharmaceuticals during the first quarter worth about $106,000. Gilder Gagnon Howe & Co. LLC bought a new stake in Catabasis Pharmaceuticals during the third quarter worth about $138,000. Oppenheimer & Co. Inc. bought a new stake in Catabasis Pharmaceuticals during the first quarter worth about $144,000. Federated Investors Inc. PA boosted its stake in Catabasis Pharmaceuticals by 45.1% in the fourth quarter. Federated Investors Inc. PA now owns 160,000 shares of the biotechnology company’s stock worth $578,000 after buying an additional 49,750 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Catabasis Pharmaceuticals by 64.4% in the first quarter. Vanguard Group Inc. now owns 368,893 shares of the biotechnology company’s stock worth $590,000 after buying an additional 144,568 shares in the last quarter. 61.43% of the stock is currently owned by hedge funds and other institutional investors.
Catabasis Pharmaceuticals Company Profile
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Stock Ratings for Catabasis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.